Avsar.

Healthcare · Pharmaceuticals

Corona Remedies Ltd (CORONA)

₹2,071.50

Mkt cap
₹12,844 Cr
P/E ratio
60.70
P/B
16.98
Div yield
0.48%
ROE
29.50%
ROCE
33.30%
EPS (TTM)
₹34.13
Book value
₹122
52W range
1,348–2,166
Sector
Healthcare

Price history

Previous close

Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas. [1]

NSE CORONABSE 544644
Health check
Mixed
ValuationExpensive
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−4.35% from high
₹2,072
₹1,348+53.71% from low₹2,166
Current
₹2,071.50
Prev close
₹2,094.00
Day
−1.07%
Price performance
1D
−1.07%
1W
+1.03%
1M
+0.62%
3M
+16.97%
6M
+34.05%
1Y
—
YTD
+43.51%

Financials

Revenue, profit & margin
P/E ratio
60.7×
CORONA is 79% above the sector median of 34.0×
CORONA60.7×
Sector median34.0×
 Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Trend
Sales314298294347361342353422
Expenses247228239277283259291329
Operating Profit6769547078836293
OPM %21%23%18%20%22%24%18%22%
Other Income21122-1743
Interest32222213
Depreciation910109991013
Profit before tax5758436170555480
Tax %25%23%28%24%25%25%17%25%
Net Profit4345314652414560
EPS in Rs7.037.325.127.598.536.747.379.83
Raw PDF

Earnings

Results dates & reactions
No upcoming results date on calendar.

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move +0.33% · closed higher next day 1 of last 1
 Q1FY27
Broadcast31 Jul '26◦
Earnings day+0.33%
+1 day+2.90%
+5 days−0.83%
+15 days+2.39%
+30 days—
FilingXBRL

Corporate actions

Last 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Results analysis

Shareholding

as of Jun 2026
69.00%Promoter
Promoters69.00%
FIIs3.63%1.38
DIIs12.90%5.88
Public14.47%7.28
Ownership trend

Peers

8 companies
Valuation vs quality
P/E × ROCE · bubble = market cap
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
SUNPHARMA₹1,899.0036.074,55,6340.84%2,901+5.95%15,300+10.46%20.53%
DIVISLAB₹9,100.0081.092,41,5760.33%902+65.50%3,080+27.80%21.97%
TORNTPHARM₹4,857.0082.801,84,7450.78%566+5.79%4,921+54.85%15.19%
CIPLA₹1,385.0031.261,11,8880.94%786−39.19%7,119+2.33%15.49%
ZYDUSLIFE₹1,120.0022.951,11,7200.09%990−35.09%8,017+21.96%21.14%
LAURUSLABS₹1,840.0090.9399,4170.11%362+125.49%2,026+29.10%17.76%
LUPIN₹2,110.0016.2096,4830.85%1,417+16.08%8,277+32.04%29.93%
CORONA₹2,100.1060.6612,8440.48%60+29.53%422+21.90%33.29%
Median: 158 Co.₹421.5033.962,2770.08%13+30.25%164+18.67%14.96%

Filings

Annual reports1
Annual Report 2026bse
Concall transcripts10
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptJan 2026PPTJan 2026RECJan 2026
Credit ratings1
Rating update 9 Febcare
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 20 Aug - Company officials will attend Phillip Capital PCG investor conference in Ahmedabad on August 26, 2026.Announcement under Regulation 30 (LODR)-Earnings Call Transcript 10 Aug - Transcript of Earnings Call with Analyst / Investor on Unaudited Financial Results for the first quarter and three months ended June 30, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 AugAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 3 Aug - Q1 FY27 earnings conference call audio recording available on company website.Announcement under Regulation 30 (LODR)-Newspaper Publication 1 Aug - Newspaper Publication of Unaudited Financial Results for the first quarter and three months ended June 30, 2026